Arcutis Director Sells $121,000 Amid ZORYVE Revenue Surge
A biotech insider sale of about $121,000 sits beside a strong ZORYVE revenue story. This article breaks down what it ...
Rebalancing can affect how withdrawal rates hold up over time. Learn factors that influence stability and how to adjust portfolio rules.
24,481 articlesA biotech insider sale of about $121,000 sits beside a strong ZORYVE revenue story. This article breaks down what it ...
As cloud-native tools reshape how enterprises build and store data, investors must decide between GitLab and MongoDB....
The second half of 2026 could reward investors who pick AI stock winners with durable competitive advantages. This gu...
A single quarterly filing can rewrite a fund’s star players. Tepper’s Appaloosa appears to have shifted away from NVI...
A mid-sized industrial company delivered a dramatic rally, with Powell Industries stock surges pushing shares up dram...
A major bank projects a transformative AI leap in 2026, with wide-ranging impacts on markets, energy grids, and perso...
In 2026, unicorns flush with cash face a new bottleneck: cap table gridlock. Despite record funding, ownership comple...
Gas prices in Illinois have jumped, putting the state near the top of the nation’s most expensive lists. This guide e...
Cathie Wood’s flagship fund is missing out on a tech-fueled bull run, lagging the AI-driven rally as investors rotate...
Institutional money flows into Bitcoin and Ethereum spur a new wave of adoption, while Solana, XRP, and Chainlink gro...
Meme coins surge on social buzz, but lasting value requires more than hype. This guide examines whether pepe next dog...
The AI boom is reshaping the tech stock landscape, putting Nvidia and Micron in the spotlight. This guide teases out ...